These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16538777)

  • 1. Oral regimen for metastatic neuroendocrine tumours.
    Kerr C
    Lancet Oncol; 2006 Mar; 7(3):197. PubMed ID: 16538777
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
    Kulke MH; Stuart K; Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Vincitore M; Michelini A; Fuchs CS
    J Clin Oncol; 2006 Jan; 24(3):401-6. PubMed ID: 16421420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    Future Oncol; 2015; 11(8):1275-90. PubMed ID: 25832882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab plus temozolomide: a novel treatment option for advanced neuroendocrine tumors?
    Koumarianou A; Kaltsas G
    J Clin Oncol; 2013 Mar; 31(7):975-6. PubMed ID: 23358970
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series.
    Saranga-Perry V; Morse B; Centeno B; Kvols L; Strosberg J
    Neuroendocrinology; 2013; 97(4):318-21. PubMed ID: 23296364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
    JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours.
    Koumarianou A; Antoniou S; Kanakis G; Economopoulos N; Rontogianni D; Ntavatzikos A; Tsavaris N; Pectasides D; Dimitriadis G; Kaltsas G
    Endocr Relat Cancer; 2012 Feb; 19(1):L1-4. PubMed ID: 22232542
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.
    Cheng YJ; Meng CT; Ying HY; Zhou JF; Yan XY; Gao X; Zhou N; Bai CM
    Medicine (Baltimore); 2018 Nov; 97(45):e12750. PubMed ID: 30407280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
    Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
    Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
    Fine RL; Gulati AP; Krantz BA; Moss RA; Schreibman S; Tsushima DA; Mowatt KB; Dinnen RD; Mao Y; Stevens PD; Schrope B; Allendorf J; Lee JA; Sherman WH; Chabot JA
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):663-70. PubMed ID: 23370660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab and subtype-adapted chemotherapy backbone in neuroendocrine tumors.
    Hadoux J; Ducreux M
    J Clin Oncol; 2013 Mar; 31(7):976-7. PubMed ID: 23358990
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
    Abbasi S; Kashashna A; Albaba H
    Pancreas; 2014 Nov; 43(8):1303-5. PubMed ID: 25036906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis.
    Lu Y; Zhao Z; Wang J; Lv W; Lu L; Fu W; Li W
    Medicine (Baltimore); 2018 Oct; 97(41):e12784. PubMed ID: 30313101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
    Crespo G; Jiménez-Fonseca P; Custodio A; López C; Carmona-Bayonas A; Alonso V; Navarro M; Aller J; Sevilla I; Grande E; Gajate P; Alonso-Gordoa T; Matos I; Capdevila J; Nieto B; Barriuso J
    Future Oncol; 2017 Mar; 13(7):615-624. PubMed ID: 27802780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide and thalidomide in the treatment of glioblastoma multiforme.
    Riva M; Imbesi F; Beghi E; Galli C; Citterio A; Trapani P; Sterzi R; Collice M
    Anticancer Res; 2007; 27(2):1067-71. PubMed ID: 17465245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
    Claringbold PG; Price RA; Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
    Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to A. Koumarianou et al and J. Hadoux et al.
    Chan JA; Kulke MH
    J Clin Oncol; 2013 Mar; 31(7):977-8. PubMed ID: 23565537
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.
    Bajetta E; Ferrari L; Procopio G; Catena L; Ferrario E; Martinetti A; Di Bartolomeo M; Buzzoni R; Celio L; Vitali M; Beretta E; Seregni E; Bombardieri E
    Ann Oncol; 2002 Apr; 13(4):614-21. PubMed ID: 12056713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
    Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
    J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.